For research use only. Not for therapeutic Use.
Simurosertib(Cat No.:I019929), also known as TAK-931, is an orally active, selective, and ATP-competitive inhibitor of cell division cycle 7 (CDC7) kinase. CDC7 kinase is involved in DNA replication and cell cycle progression, making it an attractive target for cancer therapy. By inhibiting CDC7 kinase, simurosertib disrupts DNA replication and induces cell cycle arrest, inhibiting cancer cell growth. It has shown promising anti-tumor activity in preclinical studies and is being investigated for treating various types of cancer. Clinical trials are ongoing to evaluate its safety and efficacy in cancer patients.
| Catalog Number | I019929 |
| CAS Number | 1330782-76-7 |
| Molecular Formula | C₁₇H₁₉N₅OS |
| Purity | ≥95% |
| IUPAC Name | 2-[(2S)-1-azabicyclo[2.2.2]octan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one |
| InChI | InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)/t13-/m0/s1 |
| InChIKey | XGVXKJKTISMIOW-ZDUSSCGKSA-N |
| SMILES | CC1=C(C=NN1)C2=CC3=C(S2)C(=O)NC(=N3)[C@@H]4CC5CCN4CC5 |
| Reference | [1]. K Iwai, et al. A novel CDC7-selective inhibitor TAK-931 with potent antitumor activity. European Journal of Cancer , 2016 , 69 (1) :S34. |
